Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb819 in Relapsed or Refractory Clear Cell Renal Cell Carcinoma
NCT05433142Phase 1Recruiting
- Sponsor
- Xencor
- Start
- Jun 2022
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of XmAb819 in clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (PRCC), non-small cell lung cancer (NSCLC) and 1 more, sponsored by Xencor. Primary endpoints: Incidence of treatment-emergent adverse events at 28 days and Incidence of dose limiting toxicities at 28 days. Started Jun 2022; status: recruiting.
02
Drugs
XmAb819
03
Conditions
clear cell renal cell carcinoma (ccRCC)papillary renal cell carcinoma (PRCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05433142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433142.